Segment reporting

9 Months Ended

Sep. 30, 2026

Segment Reporting [Abstract]

Segment reporting [Text Block]

11. Segment reporting

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance. The Company manages the business activities on a consolidated basis and operates as one reportable segment that constitutes all of the consolidated entity, which is the business of advancing the clinical development program of the Company's product, while opportunistically identifying, evaluating, and acquiring accretive assets, properties or businesses. The Company's CODM is its Chief Executive Officer. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM uses consolidated net loss to measure segment loss, allocate resources and assess performance. Additionally, the CODM reviews cash forecast models to determine where the Company will invest in planned research and development activities. As the Company's operations are comprised of a single reporting segment, the segment assets are reflected on the accompanying condensed consolidated balance sheet as Total Assets. Segment asset information is not used by the CODM to allocate resources.

The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company's single reporting segment. A reconciliation to consolidated operating expenses as the Company's single segment operating loss for the three and nine months ended September 30, 2026 and 2025 is included in the table below:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Research and development expenses:
SkinJect
Clinical, manufacturing and regulatory activities	464,223	1,114,470	2,475,511	3,568,401
Professional services and intellectual property	51,558	49,092	196,785	165,770
Teverelix
Clinical, manufacturing and regulatory activities	(1,389,137)	1,238	2,460,885	1,238
Professional services and intellectual property	37,358	-	115,699	-
CD228V
Professional services and intellectual property	80,649	-	80,649	-
Salaries and benefits	2,708,130	519,983	4,235,336	1,395,152
Total research and development expenses	1,952,780	1,684,783	9,564,865	5,130,561
Total general and administrative expenses	2,507,476	5,024,082	14,971,257	12,720,666
Total In-Process Research and Development (IPR&D) expenses	10,000,000	8,717,475	10,000,000	8,717,475
Total operating expenses	14,460,256	15,426,340	34,536,122	26,568,702
Other income (expense):
Interest income (expense), net	(712,652)	11,572	(1,236,441)	75,442
Loss on SEPA settlements	-	(157,721)	(127,083)	(157,721)
Change in fair value of debentures	-	(383,823)	-	(583,823)
Loss on extinguishment of debentures	-	(25,000)	-	(25,000)
Total other income (expense)	(712,652)	(554,972)	(1,363,524)	(691,102)
Net loss for the period	(15,172,908)	(15,981,312)	(35,899,646)	(27,259,804)